We are discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders.

Focused on anxiety, depression and dementia, we are advancing a pipeline of high potential therapeutics designed to meaningfully improve neuropsychiatric care.

Neuropsychiatric disorders present an overwhelming health and socioeconomic challenge affecting millions of people and their families across the United States.


adults experience at least one Major Depressive Disorder (MDD) episode 1


adults suffer from anxiety disorders, making these the most common neuropsychiatric disorders in the US 2


of patients with MDD also have comorbid anxiety 1


adults are afflicted by neurodegenerative disorders: 5M+ Alzheimer’s Disease, 1M+ Parkinson’s Disease 3


spent annually related to people with anxiety, depression and dementia 4


adults experience Post-Traumatic Stress Disorder (PTSD) each year 2

Psy is addressing critical neuropsychiatric needs through innovation, proven expertise and deep commitment

Meet Our Team

Our mission-driven team includes leading scientists, clinicians and business-building executives dedicated to delivering impactful therapies for people with CNS disorders.

Check Out Our Pipeline

Our risk-balanced pipeline consists of eight compelling drug programs primarily focused on anxiety, depression and dementia.

Explore Our Approach

We combine our deep expertise in neuropsychiatric drug development with innovative technologies to create significant value for those we serve.

1 Sources: NIMH
2 Sources: Anxiety and Depression Association of America (ADAA)
3 Sources: Parkinson’s Foundation, Alzheimer’s Association
4 Sources: Alzheimer’s Association, ADAA, NIH/WHO